登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603368 证券简称：柳药集团 公告编号：2025-094 转债代码：113563 转债简称：柳药转债 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 问题征集方式：投资者可于2025年11月27日（星期四）至12月3日(星期三)16:00前登录上证路演中心 网站首页点击"提问预征集"栏目或通过公司邮箱lygf@lzyy.cn进行提问。公司将在2025年第三季度业绩 说明会（以下简称"本次业绩说明会"）上对投资者普遍关注的问题进行回答。 广西柳药集团股份有限公司（以下简称"公司"）已于2025年10月30日在上海证券交易所网站 （http://www.sse.com.cn）披露《2025年第三季度报告》，为便于广大投资者更全面深入地了解公司 2025年第三季度的经营成果、财务状况，公司决定于2025年12月4日（星期四）15:00-16:00召开本次业 绩说明会，就投资者关心的问题进行交流。 一、说明会类型 如有特殊情况，参加人员可能发生调 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-094 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 问题征集方式：投资者可于2025年11月27日（星期四）至12月3日(星期 三)16:00前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lygf@lzyy.cn进行提问。公司将在2025年第三季度业绩说明会（以下简称"本次 业绩说明会"）上对投资者普遍关注的问题进行回答。 广西柳药集团股份有限公司（以下简称"公司"）已于2025年10月30日在上 海证券交易所网站（http://www.sse.com.cn）披露《2025年第三季度报告》，为便 于广大投资者更全面深入地了解公司2025年第三季度的经营成果、财务状况，公 司决定于2025年12月4日（星期四）15:00-16:00 ...

Core Insights - Guangxi Yulin Wantong Pharmaceutical Co., Ltd. has been established with a registered capital of 15 million yuan [1] - The company is indirectly wholly owned by Liuyuan Group (603368) [1] - The business scope includes drug production and road cargo transportation (excluding hazardous goods) [1] Company Summary - The legal representative of Guangxi Yulin Wantong Pharmaceutical Co., Ltd. is Zhu Xianhua [1] - The establishment of this company indicates potential expansion in the pharmaceutical sector by Liuyuan Group [1] Industry Implications - The inclusion of drug production in the company's business scope suggests a focus on the pharmaceutical industry, which may present investment opportunities [1] - The road cargo transportation aspect indicates a logistical component that could enhance distribution capabilities for pharmaceutical products [1]

Core Viewpoint - Liuyao Group experienced a decline in stock price and trading volume, indicating potential challenges in market performance and investor sentiment [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Liuyao Group reported a revenue of 15.758 billion, a year-on-year decrease of 1.47% [2]. - The net profit attributable to shareholders for the same period was 646 million, reflecting a year-on-year decline of 9.81% [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.789 billion, with 720 million distributed over the past three years [2]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of Liuyao Group's shareholders decreased by 7.62% to 30,400 [2]. - The average number of circulating shares per shareholder increased by 8.25% to 13,050 shares [2]. - On November 20, 2023, Liuyao Group's financing buy-in was 134.65 million, while the financing repayment was 354.12 million, resulting in a net financing outflow of 219.47 million [1]. Group 3: Stock and Trading Data - On November 20, 2023, Liuyao Group's stock price fell by 0.81%, with a trading volume of 93.9717 million [1]. - The total financing and securities lending balance for Liuyao Group was 498 million, which is 6.78% of its market capitalization, indicating a low financing level compared to the past year [1]. - The company had a securities lending balance of 337,600, which is below the 30th percentile of the past year, suggesting low short-selling activity [1].

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.51% on November 17, with the leading stock, Kaikai Industrial, falling significantly [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the SPD sector included: - Langma Information: closed at 14.57, up 1.75% with a trading volume of 69,100 shares and a turnover of 100 million yuan - Dashi Intelligent: closed at 3.04, up 1.00% with a trading volume of 527,100 shares and a turnover of 160 million yuan - Guoxin Health: closed at 10.05, up 0.60% with a trading volume of 103,900 shares and a turnover of 104 million yuan [1] - Major decliners included: - Kaikai Industrial: closed at 14.83, down 4.14% with a trading volume of 312,500 shares and a turnover of 463 million yuan - Jianfa Zhixin: closed at 34.76, down 3.44% with a trading volume of 137,400 shares and a turnover of 481 million yuan - Yingte Group: closed at 11.85, down 2.79% with a trading volume of 87,300 shares and a turnover of 104 million yuan [2] Capital Flow - The SPD sector saw a net outflow of 244 million yuan from institutional investors, while retail investors contributed a net inflow of 241 million yuan [2] - The detailed capital flow for selected stocks showed: - Guokai Hengtai: net inflow of 7.31 million yuan from institutional investors - Dashi Intelligent: net outflow of 8.11 million yuan from retail investors - Langma Information: net outflow of 1.80 million yuan from retail investors [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 1.62% on November 17, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Renmin Tongtai (600829) with a closing price of 16.64, up 9.98% and a trading volume of 768,000 shares, totaling 1.276 billion yuan [1] - Other stocks in the sector showed mixed results, with several companies like Shanghai Pharmaceuticals (601607) and Guoyao Yizhi (000028) experiencing declines of 1.20% and 1.53% respectively [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 875 million yuan from institutional investors, while retail investors contributed a net inflow of 674 million yuan [2] - The data indicates that retail investors were more active in the market compared to institutional investors during this period [2] Individual Stock Capital Flow - Key stocks with significant capital flow include: - Shuyuan Pingmin (301017) with a net inflow of 17.85 million yuan from institutional investors, while retail investors had a net outflow of 35.94 million yuan [3] - Nanjing Pharmaceutical (600713) had a net inflow of 17.30 million yuan from institutional investors, but also saw outflows from retail investors [3] - Guoyao Yizhi (000028) and Shanghai Pharmaceuticals (601607) also experienced mixed capital flows, with institutional inflows but retail outflows [3]

Group 1 - The core viewpoint of the articles highlights the recognition of seven listed companies in Guangxi for their high-quality information disclosure, achieving the highest rating of A-level, which represents a significant increase from the previous year [1] - The seven companies that received the A-level rating include Liugong, Beibu Gulf Port, Guohai Securities, Guilin Sanjin, Guiguan Electric Power, Liuyao Co., and Huayuan Co., with Guilin Sanjin achieving this rating for 13 consecutive years [1] - The improvement in information disclosure quality is seen as a benchmark for Guangxi's capital market, emphasizing the importance of transparency and compliance in fostering investor trust [1] Group 2 - The China Listed Companies Association recently announced the results of the 2025 internal control best practice case collection, with two companies from Guangxi recognized for their exemplary practices [2] - Guangxi Fenglin Wood Industry Group's submission on the intelligent internal control system based on "Beidou + Big Data + AI" was selected as a best practice case, while Beibu Gulf Port's submission on internal control for efficient operations was recognized as an excellent case [2] - The initiative aims to enhance corporate compliance and risk prevention, contributing to the establishment of a "Chinese model" for internal control practices [2]

Core Points - The company has provided a guarantee of 75.9773 million yuan to support the production and business development of its subsidiary as of October 2025 [1] - The total amount of guarantees provided by the company and its subsidiaries is 2,301.5735 million yuan, accounting for 30.19% of the latest audited net assets [7] - The board of directors has approved the guarantee arrangement, considering the business development needs and financing requirements [6] Summary by Sections Guarantee Overview - The company has provided a total guarantee of 75.9773 million yuan for its subsidiaries, while releasing guarantees totaling 204.4248 million yuan [1] - The guarantees are classified as routine guarantees, with the latest asset-liability ratio of the guaranteed parties exceeding 70% [1] Internal Decision-Making Process - The board of directors held a meeting on March 26, 2025, and approved the guarantee limit for 2025, allowing a total guarantee amount not exceeding 7 billion yuan [1][6] Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary and reasonable to meet the funding needs of the subsidiaries, which are under the company's absolute control [5] - The company can effectively manage the financial risks associated with the guarantees due to its control over the subsidiaries' operations and financial conditions [5][6] Board of Directors' Opinion - The board believes that providing guarantees to subsidiaries is a rational decision based on business development and financing needs, which will benefit the company's main operations [6] Cumulative External Guarantee Amount - As of the announcement date, the total external guarantees amount to 2,301.5735 million yuan, with no overdue guarantees reported [7]

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-093 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于为下属控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 广西南宁柳药药业有限公司（简称"南宁柳药"） | | --- | --- | --- | --- | | | 本次担保金额 | 万元 1,597.73 | | | 担保 对象一 | 实际为其提供的担保余额 | 115,039.70 | 万元（含本次） | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | □不适用：_________ | | 担保 | 被担保人名称 | | 广西百色柳药药业有限公司（简称"百色柳药"） | | | 本次担保金额 | 1,000.00 万元 | | | ...